Teva Reports Second Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Teva Reports Second Quarter 2016 Results
August 8, 2016 6:53 AM EDT
Mizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00), following the company's 2Q earnings report. TEVA reported revenue of $5.0B and $1.25 EPS, vs. $4.88B and $1.20 consensus and management's recent guidance of $4.9- $5.0B and... More
August 5, 2016 7:27 AM EDT
Oppenheimer downgraded Teva Pharma (NYSE: TEVA) from Outperform to Perform and removed its price target (prior $72.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $55.45 yesterday.
...
More
August 4, 2016 7:05 AM EDT
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $1.25, $0.05 better than the analyst estimate of $1.20. Revenue for the quarter came in at $5 billion versus the consensus estimate of $4.87 billion.
We are pleased with our performance this quarter and the steps we are taking to transform our business, notably the recent... More
